(3)Commission Implementing Regulation (EU) 2023/52note authorised the placing on the market of ‘3-Fucosyllactose produced by a derivative strain of Escherichia coli BL21 (DE3)’ for use in infant formula, follow-on formula, processed cereal-based foods for infants and young children, and baby foods for infants and young children, as defined under Regulation (EU) No 609/2013 of the European Parliament and of the Councilnote, milk based drinks and similar products intended for young children, foods for special medical purposes for infants and young children as defined under Regulation (EU) No 609/2013, foods for special medical purposes as defined under Regulation (EU) No 609/2013, excluding foods for infants and young children, and food supplements as defined in Directive 2002/46/EC of the European Parliament and of the Councilnote, for the general population, excluding infants and young children.